20080103
 Bad Cancer Tests Drawing Scrutiny   By Anna Wilde Mathews, The Wall Street Journal,  Jan 4, 2008  The tests are used to help determine whether women with invasive breast cancer will receive drugs such as Genentech Inc.'s Herceptin, GlaxoSmithKline PLC's Tykerb and a number of antihormone medications, including the generic tamoxifen and newer treatments such as AstraZeneca PLC's Arimidex and Faslodex. In another analysis of labs in multiple countries, published online last August in the Journal of Clinical Oncology, 70% of 105 patients scored as negative on the estrogen test were relabeled as positive when the tissue was retested by an experienced lab.   
